

Renal Function at Two Years in Liver Transplant Patients Randomized, Multicenter Study

American Journal of Transplantation

13, 1734-1745

DOI: [10.1111/ajt.12280](https://doi.org/10.1111/ajt.12280)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Orthotopic liver transplantation. , 2012, , 1722-1736.e4.		2
2	Kidney Disease in the Setting of Liver Failure: Core Curriculum 2013. American Journal of Kidney Diseases, 2013, 62, 1198-1212.	2.1	26
3	Preserving Flow in Liver Transplant Recipients: mTOR Inhibitors Everolimus and Sirolimus Are Not Peas From a Pod. American Journal of Transplantation, 2013, 13, 1633-1635.	2.6	3
4	Sirolimus as a calcineurin inhibitor- and renal-sparing agent: All good things come to those who wait versus spare the nephron, spoil the patient. Liver Transplantation, 2013, 19, 787-789.	1.3	1
5	The role of everolimus in liver transplantation. Clinical and Experimental Gastroenterology, 2014, 7, 329.	1.0	35
6	The role of mTOR inhibitors in the prevention of organ rejection in adult liver transplant patients: a focus on everolimus. Transplant Research and Risk Management, 0, , 31.	0.7	0
7	Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. Liver Transplantation, 2014, 20, 25-34.	1.3	31
8	Evolution of donor-specific antibodies (<scp>DSA</scp>) and incidence of <i>de novo</i> <scp>DSA</scp> in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors. Clinical Transplantation, 2014, 28, 1054-1060.	0.8	17
9	Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation. Clinical Transplantation, 2014, 28, 797-801.	0.8	21
10	Everolimus Inhibits Anti-HLA I Antibody-Mediated Endothelial Cell Signaling, Migration and Proliferation More Potently Than Sirolimus. American Journal of Transplantation, 2014, 14, 806-819.	2.6	85
11	Everolimus-Based Immunosuppression in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Liver Transplantation: A Case Series. Transplantation Proceedings, 2014, 46, 3496-3501.	0.3	34
13	Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation. Pharmacogenetics and Genomics, 2014, 24, 427-435.	0.7	10
14	Everolimus in liver transplantation. Current Opinion in Organ Transplantation, 2014, 19, 578-582.	0.8	19
15	Oedema, solid organ transplantation and mammalian target of rapamycin inhibitor/proliferation signal inhibitors (mTOR-I/PSIs). CKJ: Clinical Kidney Journal, 2014, 7, 115-120.	1.4	27
16	Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience. Hepatology International, 2014, 8, 137-145.	1.9	22
17	The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy. Clinical Transplantation, 2014, 28, 635-648.	0.8	28
18	Angiosarcoma successfully treated with liver transplantation and sirolimus. Pediatric Transplantation, 2014, 18, E114-9.	0.5	20
19	Sirolimus and mTOR Inhibitors in Liver Transplantation: The Wheel Has Come Full Circle. American Journal of Transplantation, 2014, 14, 249-250.	2.6	3

#	ARTICLE	IF	CITATIONS
21	Improving Long-Term Outcomes After Liver Transplantation. <i>Clinics in Liver Disease</i> , 2014, 18, 717-730.	1.0	24
22	Renal Dysfunction in End-Stage Liver Disease and Post-Liver Transplant. <i>Clinics in Liver Disease</i> , 2014, 18, 543-560.	1.0	25
23	Current strategies for immunosuppression following liver transplantation. <i>Langenbeck's Archives of Surgery</i> , 2014, 399, 981-988.	0.8	17
24	Calcineurin Inhibitor Free De Novo Immunosuppression in Liver Transplant Recipients With Pretransplant Renal Impairment. <i>Transplantation</i> , 2015, 99, 2565-2575.	0.5	20
25	Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus. <i>Transplantation</i> , 2015, 99, 1455-1462.	0.5	109
26	Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain. <i>Liver Transplantation</i> , 2015, 21, 1056-1065.	1.3	35
27	Update on the management of the liver transplant patient. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 224-232.	1.0	8
28	Review on immunosuppression in liver transplantation. <i>World Journal of Hepatology</i> , 2015, 7, 1355.	0.8	184
29	An Update of Liver Transplantation for Nonalcoholic Steatohepatitis. <i>Current Hepatology Reports</i> , 2015, 14, 99-108.	0.4	0
30	Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 118.	0.7	10
31	Everolimus in de novo liver transplant recipients: a systematic review. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2015, 14, 461-469.	0.6	23
32	A pocket guide to identify patients at risk for chronic kidney disease after liver transplantation. <i>Transplant International</i> , 2015, 28, 519-528.	0.8	16
33	Lack of agreement for defining "clinical suspicion of rejection" in liver transplantation: a model to select candidates for liver biopsy. <i>Transplant International</i> , 2015, 28, 455-464.	0.8	29
34	From immunosuppression to tolerance. <i>Journal of Hepatology</i> , 2015, 62, S170-S185.	1.8	133
35	Infections After Transplantation. , 2015, , 1006-1039.		2
37	Everolimus is safe within the first month after liver transplantation. <i>Transplant Immunology</i> , 2015, 33, 146-151.	0.6	9
38	Transplantation Immunology. , 2015, , 3-32.		0
39	Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses. <i>PLoS ONE</i> , 2016, 11, e0156535.	1.1	11

#	ARTICLE	IF	CITATIONS
40	Do patient characteristics influence efficacy and renal outcomes in liver transplant patients receiving everolimus?. <i>Clinical Transplantation</i> , 2016, 30, 279-288.	0.8	9
41	Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal. <i>Transplant International</i> , 2016, 29, 961-973.	0.8	57
42	Selection and use of immunosuppressive therapies after liver transplantation: current German practice. <i>Clinical Transplantation</i> , 2016, 30, 487-501.	0.8	22
43	Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the <scp>PROTECT</scp> randomized liver transplantation study. <i>Clinical Transplantation</i> , 2016, 30, 741-748.	0.8	38
45	Therapeutic Drug Monitoring of Everolimus. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 143-169.	1.0	102
46	Cost-effectiveness of everolimus plus reduced tacrolimus in de novo liver-recipients in the Italian setting. <i>Journal of Medical Economics</i> , 2016, 19, 866-873.	1.0	2
47	Use of everolimus in liver transplantation: The French experience. <i>Transplantation Reviews</i> , 2016, 30, 161-170.	1.2	19
49	The Role of mTOR Inhibitors in Solid Organ Transplantation. , 2016, , 293-315.		1
50	Roadmap for improving patient and graft survival in the next 10 years. <i>Liver Transplantation</i> , 2016, 22, 71-78.	1.3	19
51	Protecting the Kidney in Liver Transplant Recipients: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice. <i>American Journal of Transplantation</i> , 2016, 16, 2532-2544.	2.6	109
52	The efficacy and safety of mammalian target of rapamycin inhibitors ab initio after liver transplantation without corticosteroids or induction therapy. <i>Digestive and Liver Disease</i> , 2016, 48, 315-320.	0.4	10
53	Safety of mTOR inhibitors in adult solid organ transplantation. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 303-319.	1.0	91
54	EASL Clinical Practice Guidelines: Liver transplantation. <i>Journal of Hepatology</i> , 2016, 64, 433-485.	1.8	744
55	Overview of the pharmacology and toxicology of immunosuppressant agents that require therapeutic drug monitoring. , 2016, , 1-27.		2
56	Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. <i>Immunotherapy</i> , 2017, 9, 197-206.	1.0	1
57	Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. <i>American Journal of Transplantation</i> , 2017, 17, 1843-1852.	2.6	79
58	Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients. <i>Transplantation</i> , 2017, 101, S1-S56.	0.5	217
59	Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 123-136.	1.0	30

#	ARTICLE	IF	CITATIONS
60	Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. The Cochrane Library, 2017, 2017, CD011639.	1.5	35
61	Limitations of current liver transplant immunosuppressive regimens: renal considerations. Hepatobiliary and Pancreatic Diseases International, 2017, 16, 27-32.	0.6	22
62	Conversion From Sirolimus to Everolimus in Long-Term Liver Graft Recipients. Journal of Clinical Pharmacology, 2017, 57, 837-845.	1.0	7
63	Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation. Transplantation, 2017, 101, 2873-2882.	0.5	46
64	Recomendaciones de uso de everolimus en el trasplante hepático. Gastroenterología Y Hepatología, 2017, 40, 629-640.	0.2	2
65	Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study. Pediatric Transplantation, 2017, 21, e13024.	0.5	18
66	Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients. Transplantation, 2017, 101, 341-349.	0.5	8
67	Recommendations of everolimus use in liver transplant. Gastroenterología Y Hepatología (English) Tj ETQq1 1 0.784314 rgBT /Overl	0.0	1
68	Use of Everolimus in Liver Transplantation. Transplantation, 2017, 101, 239-251.	0.5	54
69	Modification of immunosuppressive therapy as risk factor for complications after liver transplantation. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 199-209.	1.0	22
70	Liver and pancreas transplantation immunobiology. , 2017, , 1726-1736.e3.		0
71	Conversion to Mycophenolate Mofetil Monotherapy in Liver Recipients: Calcineurin Inhibitor Levels are Key. Annals of Hepatology, 2017, 16, 94-106.	0.6	5
72	Real-World Multicenter Experience of Immunosuppression Minimization Among 661 Liver Transplant Recipients. Annals of Transplantation, 2017, 22, 265-275.	0.5	8
73	International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation, 2018, 102, 727-743.	0.5	178
74	Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients. Transplantation Proceedings, 2018, 50, 175-183.	0.3	9
75	Influence of Blood Pressure and Calcineurin Inhibitors on Kidney Function After Heart or Liver Transplantation. Transplantation, 2018, 102, 845-852.	0.5	15
76	mTOR Inhibition and Clinical Transplantation. Transplantation, 2018, 102, S19-S26.	0.5	16
77	Everolimus vs Mycophenolate Mofetil in Combination With Tacrolimus: A Propensity Score-matched Analysis in Liver Transplantation. Transplantation Proceedings, 2018, 50, 3615-3620.	0.3	13

#	ARTICLE	IF	CITATIONS
78	Acute Kidney Injury After Liver Transplantation. <i>Transplantation</i> , 2018, 102, 1636-1649.	0.5	89
80	Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years. <i>Liver Transplantation</i> , 2019, 25, 1822-1832.	1.3	26
81	Efficacy and safety of everolimus treatment on liver transplant recipients: A meta-analysis. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13179.	1.7	13
82	Everolimus: Longer-term CERTITUDE. <i>Liver Transplantation</i> , 2019, 25, 1745-1746.	1.3	0
83	Is everolimus linked to metabolic syndrome in liver transplant recipients?. <i>Indian Journal of Gastroenterology</i> , 2019, 38, 348-355.	0.7	1
84	mTOR Inhibitor Everolimus in Regulatory T Cell Expansion for Clinical Application in Transplantation. <i>Transplantation</i> , 2019, 103, 705-715.	0.5	28
86	Cross-sectional analysis of immunosuppressive regimens focused on everolimus after liver transplantation in a Korean high-volume transplantation center. <i>Korean Journal of Transplantation</i> , 2019, 33, 98.	0.0	6
87	The Measurement of Donor-Specific Cell-Free DNA Identifies Recipients With Biopsy-Proven Acute Rejection Requiring Treatment After Liver Transplantation. <i>Transplantation Direct</i> , 2019, 5, e462.	0.8	29
88	Area Under Trough Concentrations of Tacrolimus as a Predictor of Progressive Renal Impairment After Liver Transplantation. <i>Transplantation</i> , 2019, 103, 2539-2548.	0.5	17
89	Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial. <i>Liver Transplantation</i> , 2019, 25, 242-251.	1.3	27
90	Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis. <i>Transplant Infectious Disease</i> , 2019, 21, e13047.	0.7	15
91	mTOR inhibitors in pediatric liver transplant recipients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 403-409.	0.7	11
92	Nonalcoholic Steatohepatitis After Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 141-159.	1.3	49
93	Incidence, Predictors, and Impact on Survival of Long-term Cardiovascular Events After Liver Transplantation. <i>Transplantation</i> , 2020, 104, 317-325.	0.5	14
94	Renal disease in the allograft recipient. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 46-47, 101690.	1.0	9
95	NAFLD and liver transplantation: Disease burden, current management and future challenges. <i>JHEP Reports</i> , 2020, 2, 100192.	2.6	96
96	Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. <i>Hepatology International</i> , 2020, 14, 930-943.	1.9	37
97	Time to Conversion to an Everolimus-Based Regimen: Renal Outcomes in Liver Transplant Recipients From the EVEROLIVER Registry. <i>Liver Transplantation</i> , 2020, 26, 1465-1476.	1.3	23

#	ARTICLE	IF	CITATIONS
98	Acute and chronic kidney disease after pediatric liver transplantation: An underestimated problem. <i>Clinical Transplantation</i> , 2020, 34, e14082.	0.8	8
99	Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 165-178.	1.0	3
100	Immune and gene expression profiling during tacrolimus to everolimus conversion early after liver transplantation. <i>Human Immunology</i> , 2021, 82, 81-88.	1.2	4
101	Metabolic and Renal Effects of Mammalian Target of Rapamycin Inhibitors Treatment After Liver Transplantation: Real-Life Single-Center Experience. <i>Transplantation Proceedings</i> , 2021, 53, 221-227.	0.3	2
102	Real-World Efficacy and Safety of Everolimus with Low Dose Tacrolimus in Liver Transplantation Recipients. <i>Korean Journal of Clinical Pharmacy</i> , 2021, 31, 44-52.	0.0	0
103	Early use of everolimus improved renal function after adult deceased donor liver transplantation. <i>Korean Journal of Transplantation</i> , 2021, 35, 8-14.	0.0	0
104	Exposure-response modeling for extrapolation from adult to pediatric patients who differ with respect to prognostic factors: Application to everolimus. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 589-598.	1.3	3
105	Post-Liver Transplant Acute Kidney Injury. <i>Liver Transplantation</i> , 2021, 27, 1653-1664.	1.3	23
106	Position paper on liver and kidney diseases from the Italian Association for the Study of Liver (AISF), in collaboration with the Italian Society of Nephrology (SIN). <i>Digestive and Liver Disease</i> , 2021, 53, S49-S86.	0.4	7
107	The effect of early everolimus administration on the renal function while reducing the dosage of calcineurin inhibitors in liver transplant recipients in a long-term follow-up. <i>Transplantologia</i> , 2021, 13, 121-129.	0.1	1
108	Prognostic impact of early recovering acute kidney injury following liver transplantation. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	0.5	1
109	Comment on: Acute rejection after liver transplantation is less common, but predicts better prognosis in HBV-related hepatocellular carcinoma patients. <i>International Journal of Surgery Case Reports</i> , 2021, 84, 106073.	0.2	0
110	Is There a Place for Induction Therapy With Polyclonal Antibodies to Improve Renal Function After Liver Transplantation?. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	0.5	0
111	Kidney Failure after Liver Transplantation. <i>Transplantology</i> , 2021, 2, 315-335.	0.3	3
112	Early Everolimus-Facilitated Reduced Tacrolimus in Liver Transplantation: Results From the Randomized HEPHAISTOS Trial. <i>Liver Transplantation</i> , 2022, 28, 998-1010.	1.3	15
113	Outcome and safety of a surveillance biopsy guided personalized immunosuppression program after liver transplantation. <i>American Journal of Transplantation</i> , 2022, 22, 519-531.	2.6	19
114	An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients. <i>Transplantation Reviews</i> , 2021, 36, 100655.	1.2	15
115	An Essential Guide for Managing Post-Liver Transplant Patients: What Primary Care Physicians Should Know. <i>American Journal of Medicine</i> , 2022, 135, 157-166.	0.6	4

#	ARTICLE	IF	CITATIONS
116	Immunosuppression: Induction and immediate maintenance in liver transplant recipients. <i>Gastroenterology, Hepatology and Endoscopy Practice</i> , 2021, 1, 89.	0.1	0
117	Long-Term Outcomes of Everolimus Therapy in De Novo Liver Transplantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Transplantation Proceedings</i> , 2021, 53, 148-158.	0.3	9
118	Immunosuppression in liver transplant. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 46-47, 101681.	1.0	59
119	Efficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled Trials. <i>Transplantation</i> , 2021, 105, 1564-1575.	0.5	27
120	Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence from an International Randomized Trial of Everolimus-Based Immunosuppression. <i>Annals of Transplantation</i> , 2018, 23, 751-757.	0.5	19
121	Prevalence and progression of chronic kidney disease after a liver transplant: a prospective, real-life, observational, two-year multicenter study. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 538-543.	0.1	10
122	Everolimus with or without mycophenolate mofetil in a liver transplantation setting: a single-center experience. <i>Annals of Gastroenterology</i> , 2018, 31, 613-620.	0.4	4
123	Prognostic value of endogenous and exogenous metabolites in liver transplantation. <i>Biomarkers in Medicine</i> , 2020, 14, 1165-1181.	0.6	2
124	Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study. <i>World Journal of Gastroenterology</i> , 2016, 22, 8869.	1.4	22
125	Management of immunosuppressant agents following liver transplantation: Less is more. <i>World Journal of Hepatology</i> , 2016, 8, 148.	0.8	16
126	Use of everolimus in liver transplantation. <i>World Journal of Hepatology</i> , 2017, 9, 990.	0.8	22
127	Update on Immunosuppression in Liver Transplantation. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2019, 9, 96-101.	0.1	25
128	Multiple indications for everolimus after liver transplantation in current clinical practice. <i>World Journal of Transplantation</i> , 2014, 4, 122.	0.6	9
129	What's new in clinical solid organ transplantation by 2013. <i>World Journal of Transplantation</i> , 2014, 4, 243.	0.6	19
130	The Kidney in Nonrenal Solid Organ Transplantation: Liver and Heart. , 2015, , 173-183.		0
131	Orthotopic liver transplantation. , 2017, , 1801-1815.e5.		1
132	Everolimus in clinical practice after liver transplantation: a single-center experience. <i>Vestnik Transplantologii i Iskusstvennykh Organov</i> , 2017, 19, 34-40.	0.1	1
134	Effect of everolimus rescue therapy for acute cellular rejection following pediatric living donor liver transplantation: Report of one case. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2020, 24, 216-220.	0.1	1

#	ARTICLE	IF	CITATIONS
135	Strategies to Improve Immune Suppression Post-Liver Transplantation: A Review. <i>Transplantation</i> , 2021, 2, 441-454.	0.3	2
137	Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence. <i>Annals of Gastroenterology</i> , 2015, 28, 323-330.	0.4	30
138	Changes in glomerular filtration rate in liver recipients after reduced exposure to calcineurin inhibitors with concomitant everolimus administration within the first year after immunosuppression conversion. <i>Vestnik Transplantologii I Iskusstvennykh Organov</i> , 2022, 23, 32-41.	0.1	1
139	Current aspects of renal dysfunction after liver transplantation. <i>World Journal of Hepatology</i> , 2022, 14, 45-61.	0.8	6
143	Chronic Kidney Disease After Liver Transplantation. <i>Clinics in Liver Disease</i> , 2022, 26, 323-340.	1.0	1
145	Immunosuppressive Drugs in Liver Transplant: An Insight. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1557-1571.	0.4	20
146	Current status of liver transplantation for <sc>nonâ€B nonâ€C</sc> liver cirrhosis and hepatocellular carcinoma. <i>Annals of Gastroenterological Surgery</i> , 0, , .	1.2	1
147	Population pharmacokinetics of everolimus in adult liver transplant patients: Comparison to tacrolimus disposition and extrapolation to pediatrics. <i>Clinical and Translational Science</i> , 0, , .	1.5	3
149	Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma. <i>Annals of Transplantation</i> , 0, 27, .	0.5	2
150	Immunosuppression. , 2023, , 551-562.		0
151	Three-year results of renal function in liver transplant recipients on low-dose sirolimus and tacrolimus: a multicenter, randomized, controlled trial. <i>Liver Transplantation</i> , 2023, 29, 184-195.	1.3	4